<SEC-DOCUMENT>0001062993-14-007087.txt : 20141212
<SEC-HEADER>0001062993-14-007087.hdr.sgml : 20141212
<ACCEPTANCE-DATETIME>20141212153308
ACCESSION NUMBER:		0001062993-14-007087
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20141012
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141212
DATE AS OF CHANGE:		20141212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51652
		FILM NUMBER:		141283471

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp. Form 8-K - Filed by newsfilecorp.com</TITLE>
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center>Current Report <BR>Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934 <BR></P>
<P align=center>Date of Report (Date of earliest event reported): <B><U>October
12, 2014</U></B><B> </B></P>
<P align=center><B><U><FONT size=5>ANAVEX LIFE SCIENCES CORP.</FONT></U></B><B>
</B><BR>
(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-51652 </U></B></TD>
    <TD align=center width="33%"><B><U>98-0608404 </U></B></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction </TD>
    <TD align=center width="33%">(Commission </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>of incorporation) </TD>
    <TD align=center width="33%">File Number) </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE>
<P align=center><B><U>51 West 52nd Street, 7th Floor, New York, NY USA
10019</U></B><BR>(Address of principal executive offices) (Zip Code) </P>
<P align=center>Registrant's telephone number, including area code
<B><U>1-844-689-3939</U></B></P>
<P align=center><B><U>Not Applicable</U></B><BR>(Former name or former address,
if changed since last report.)</P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</P>
<P align=justify>[&nbsp; &nbsp;] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425) </P>
<P align=justify>[&nbsp; &nbsp;] Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a -12) </P>
<P align=justify>[&nbsp;&nbsp; ] Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) </P>
<P align=justify>[&nbsp; &nbsp;] Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=justify><B>Item 8.01 Other Events. </B></P>
<P align=justify>On December 12, 2014, Anavex Life Sciences Corp., a Nevada
corporation (the &#147;<U>Company</U>&#148;), announced via press release (the &#147;<U>Press
Release</U>&#148;) that, as of December 12, 2014, its common stock is now being
quoted on the OTCQX under the Company&#146;s existing stock ticker &#147;AVXL.&#148; The OTCQX
is the highest tier of the OTC Markets Group&#146;s trading marketplace. A complete
copy of the Press Release is attached hereto as <U>Exhibit 99.1</U>. </P>
<P align=justify>The information in this <U>Item 8.01</U> of the Current Report,
including <U>Exhibit 99.1</U>, is being furnished and shall not be deemed
&#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the &#147;<U>Exchange</U> <U>Act</U>&#148;), or otherwise subject to the
liabilities of that Section. The information in this <U>Item 8.01</U> of this
Current Report shall not be incorporated by reference into any registration
statement or other document pursuant to the Securities Act of 1933, as amended,
or the Exchange Act, except as shall be expressly set forth by specific
reference in such filing.</P>
<P align=justify><B>Item 9.01.</B> <B>Financial Statements and Exhibits.
</B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>Not applicable</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>Not applicable</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>Not applicable</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify><U>Exhibits</U>.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 2px solid" align=center><B>EXHIBIT
      NO.</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 2px solid" align=center width="70%"
    ><B>DESCRIPTION</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 2px solid" align=center width="15%"
    ><B>LOCATION</B> </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="70%"  >&nbsp;</TD>
    <TD align=center width="15%"  >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-1.htm">Exhibit 99.1 </a></TD>
    <TD align=left width="70%" bgColor=#eeeeee ><a href="exhibit99-1.htm">Press Release
      dated December 12, 2014 regarding Upgrade to OTCQX </a></TD>
    <TD align=center width="15%" bgColor=#eeeeee ><a href="exhibit99-1.htm">Provided
      herewith </a></TD>
  </TR></TABLE>
<P align=center>2 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A>
<P align=center><B><U>SIGNATURES</U></B> </P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%"><B>ANAVEX LIFE SCIENCES CORP.</B> </TD></TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="50%"><I>/s/
      Christopher Missling, PhD</I> </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%">Name: Christopher Missling, PhD </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%">Title: Chief Executive Officer </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%">Date: December 12, 2014 </TD></TR></TABLE>
<P align=center>3 </P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp. - Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B>Anavex Upgrades to OTCQX Marketplace </B></P>
<P align=justify>NEW YORK, NY, December XX, 2014 &#150; <U><FONT color=#0000ff>Anavex
Life Sciences Corp</FONT></U>. (&#147;Anavex&#148; or the &#147;Company&#148;) (OTCQX: AVXL), a
clinical-stage biopharmaceutical company developing novel drug candidates to
treat Alzheimer&#146;s disease, other diseases of the central nervous system (CNS)
and various types of cancer, today announces that the Company is now trading on
the OTCQX under the Company&#146;s existing stock ticker AVXL. The OTCQX is the best
marketplace for established global and growth companies operated by OTC Markets
Group Inc. </P>
<P align=justify>To qualify for trading on the OTCQX, companies must meet high
financial standards, demonstrate compliance with U.S. securities laws, be
current in their disclosure, and be sponsored by a professional third-party
advisor. Fewer than 400 companies are currently trading on the OTCQX and they
range from global blue-chip companies to high-growth small caps. </P>
<P align=justify>&#147;Anavex is pleased to be joining the top-tier firms trading on
the OTCQX. This is another important step for our Company as we advance ANAVEX
2-73 and ANAVEX PLUS in the clinic and move forward with our pipeline of
promising compounds,&#148; said Christopher U. Missling, PhD, President and Chief
Executive Officer for Anavex. &#147;We also expect improved visibility and liquidity
of our stock to contribute to long-term shareholder value.&#148; </P>
<P align=justify>&#147;We are pleased to welcome Anavex to the OTCQX marketplace,&#148;
said R. Cromwell Coulson, President and CEO of OTC Markets Group. &#147;Growing U.S.
companies like Anavex choose OTCQX to demonstrate transparency and increase
their visibility and engagement with U.S. investors. We look forward to working
with Anavex&#146;s management team as the company continues to grow and expand its
presence in the U.S. market.&#148; </P>
<P align=justify>U.S. investors can find current financial disclosure and
Real-Time Level 2 quotes for Anavex on <U><FONT
color=#0000ff>www.otcmarkets.com. </FONT></U></P>
<P align=justify><B>About Anavex Life Sciences Corp. </B></P>
<P align=justify>Anavex Life Sciences Corp. (OTCQX: AVXL) is a publicly traded
biopharmaceutical company dedicated to the development of novel drug candidates
to treat Alzheimer&#146;s disease, other Central Nervous System (CNS) diseases, and
various types of cancer. Anavex&#146;s lead drug candidates, ANAVEX 2-73 and ANAVEX
PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept&#174;), are currently in
a Phase 2a clinical trial for Alzheimer's disease. ANAVEX 2-73 is an orally
available drug candidate that targets sigma-1 and muscarinic receptors and
successfully completed Phase 1 with a clean data profile. Preclinical studies
demonstrated its potential to halt and/or reverse the course of Alzheimer&#146;s
disease. The drug combination ANAVEX PLUS produced up to 80% greater reversal of
memory loss in Alzheimer&#146;s disease models versus when the drugs were used
individually. Further information is available at <U><FONT
color=#0000ff>www.anavex.com. </FONT></U></P>
<P align=justify><B>Forward-Looking Statements <BR></B>Statements in this press
release that are not strictly historical in nature are forward-looking
statements. These statements are only predictions based on current information
and expectations and involve a number of risks and uncertainties. Actual events
or results may differ materially from those projected in any of such statements
due to various factors, including the risks set forth in the Company&#146;s most
recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not
to place undue reliance on these forward-looking statements, which </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=justify>speak only as of the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary statement and
Anavex Life Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date hereof. </P>
<P align=justify><B>For Further Information </B><BR>Anavex Life Sciences Corp.
<BR>Research &amp; Business Development <BR>Toll-free: 1-844-689-3939 <BR>Email:
<U><FONT color=#0000ff>info@anavex.com </FONT></U><BR></P>
<P align=justify>Shareholder &amp; Media Relations <BR>Toll-free: 1-866-505-2895
<BR>Outside North America: +1 (416) 489-0092 <BR>Email: <U><FONT
color=#0000ff>ir@anavex.com</FONT></U><BR><U><FONT
color=#0000ff>www.anavex.com</FONT></U><BR></P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
